Treatment of resistance to Ado-trastuzumab emtansine

Although Ado-trastuzumab emtansine has been successfully used to treat previously treated HER2-positive breast cancer patients, primary and acquired resistance to Ado-trastuzumab emtansine remains one of the important clinical concerns. The mechanisms of resistance arise from defects in intracellular metabolism and emtansine-mediated cell killing.

Currently proposed strategies to overcome resistance to trastuzumab therapy could be the use of second-generation anti-HER2 antibody-drug conjugates that use a different linker-payload biochemical pathway. Another proposed method to overcome resistance to trastuzumab therapy is TAS0728, an irreversible and selective HER2 kinase inhibitor. In lesions that are resistant to trastuzumab, HER2-HER3 phosphorylation is preserved, which is why changing treatment to TAS0728 results in significant tumor regression due to HER2-HER3 pathway inhibition. However, everyone’s physique is different and their resistance to drugs is also different. If a patient develops drug resistance, he should inform the doctor in time and adjust the use of the drug under the guidance of the doctor.

EnmetratrastuzumabThe monoclonal antigenic drug has been launched in China and has entered the scope of medical insurance. Only eligible patients can be reimbursed. SpecificationsThe price of 100mg per box may be around 20,000 yuan. This drug is a strictly controlled drug. Listed overseas Enmei Trastuzumab The single-unit generic drug has Turkish and European versions, with specifications The price of each box of 100 mg may be around 3,000-8,000 yuan (the price may fluctuate due to the exchange rate). The ingredients of the originator drugs sold domestically and abroad are basically the same, and there are currently no generic versions of Enmei Trastuzumab produced and launched.